During IV infusion: chest tightness, a pounding heart, nausea, flushing — these are infusion-rate reactions.
Have whoever is running the drip slow it down or stop; the symptoms ease as the rate drops.
Chest pain that does not settle when the infusion stops, or trouble breathing → 911.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
NAD+ is not a drug in any conventional sense — it is a coenzyme central to metabolism, cycling between NAD+ and NADH to shuttle electrons through glycolysis, the TCA cycle and oxidative phosphorylation. Separately, it is consumed as a substrate by sirtuins, PARPs and CD38, which is what links it to DNA repair and ageing biology. Tissue NAD+ declines with age, and that observation drives the entire field.
The pharmacological problem is fundamental: NAD+ is a large, charged molecule that does not readily cross cell membranes. Administered NAD+ is substantially degraded extracellularly to nicotinamide and related metabolites, which are then taken up and re-synthesised into NAD+ intracellularly. So intravenous NAD+ is, to a considerable degree, an expensive and uncomfortable way to deliver precursors — which is precisely the argument for NMN and NR instead.
The decline of NAD+ with age is well established. That raising it produces clinical benefit in humans is not. Precursor trials (NR, NMN) reliably raise blood NAD+ levels — a biomarker — while showing inconsistent and generally modest effects on the outcomes people actually care about. Evidence for intravenous NAD+ specifically, as sold by clinics, is close to nonexistent: it rests on uncontrolled observation and a very large amount of marketing.
Not an FDA-approved drug. Sold as an oral supplement (as precursors) and administered intravenously by clinics in a regulatory grey area. Nicotinamide riboside has NDI notification status; FDA has taken the position that NMN is excluded from the dietary supplement definition because it was authorised for investigation as a new drug, a determination that remains contested.
Oral precursors are well tolerated at studied doses. Intravenous NAD+ commonly causes chest tightness, nausea and flushing during infusion, which is why it is given slowly over hours. The deeper unknown is that NAD+ metabolism is not uniformly beneficial: NAD+ is also fuel for cancer cell proliferation, and long-term consequences of chronic elevation in humans have not been established.
No established therapeutic dose. IV clinic protocols (commonly 250–1000 mg infused over hours) are not trial-validated. The actual evidence base is precursor trials — see NMN.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.